Phase 3 N=72 A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)
Primary Insomnia
Primary: Latency To Persistent Sleep (LPS) — 37.5; 24.4; 20.9; 12.8 Minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=16 Differential Diagnosis for the Causes of Subclavian Steal for Patients With Vascular Access in the Forearm
Subclavian Steal
Primary: Change of Subclavian Flow to Normal Flow Pattern During Cuff Test — 0; 2 participants
Phase 3 N=80 Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa
Anorexia Nervosa
Primary: Areal Bone Density by DXA — 0.88; 0.89 g/cm2
Phase 2 N=30 Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease
Lymphoma
Primary: Participants' Response — 23; 2; 3; 1 participants
Phase 4 N=39 Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome
Down Syndrome
Primary: Changes in Neuropsychological Measures From Baseline to End of Study — -0.22; -0.84; 0.56; 0 units on a scale — p=0.403
Phase 2 N=67 Study of Sleep-maintenance Activity of 3 Doses of SKP-1041
Sleep Disorder · Primary Insomnia
Primary: Wake After Sleep Onset During Hours 3 to 7 Post-dose (WASO 3-7) — -40.19; -48.79; -50.17; -49.34 minutes — p=0.0118
N/A N=44 Effectiveness of Nanoone Woman Underwear Using in the Management of Dysmenorrhea
Dysmenorrhea
Primary: The Mean Change in Maximum Pain Level at Each Menstrual Cycle From Baseline — -0.810; -1.29; -1.74 scores
Phase 2 N=15 PF-04191834 Single Dose Bronchodilatory Study In Asthma.
Asthma
Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) — 2.624; 2.626; 2.585; 2.579 L
Phase 2 N=41 Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Time to Progression (TTP) — 26.94 Months
Phase 2 N=20 Use of Infliximab for the Treatment of Pemphigus Vulgaris
Pemphigus
Primary: Participant Response to Treatment at Week 18 — 1; 1 Participants — p=1.00
N/A N=28 Prophylactic Bronchoscopy After Inhalation Injury in Burn Patients
Inhalation Injury · Pneumonitis · Pneumonia
Primary: All Cause Mortality — 0; 1 participants
Phase 2 N=25 A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration
Genetic Disorders · Hereditary Angioedema
Primary: HAE Attacks/Week — 0.9; 0.4 attacks/week
N/A N=79 Treatment of Androgenic Alopecia in Males
Androgenetic Alopecia · Hair Loss · Male Pattern Baldness
Primary: Changes in Terminal Hair Count at 16 and 26 Weeks Compared to Baseline in Men Diagnosed With Androgenetic Alopecia — 23.5; 20.4; 4.4; 25.7 hairs per cm^2
Phase 2 N=183 2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women
Influenza
Primary: Number of Participants Reporting Vaccine-associated Unsolicited Non-serious Adverse Events — 2; 3; 2; 0 participants
Phase 3 N=633 Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer
Breast Cancer
Primary: Relapse-free Survival Rates at 2.4 Years — 11; 20; 89; 80 percentage of participants — p=<0.001